Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS

Blue Owl Capital Holdings LP cut its position in shares of Aktis Oncology (NASDAQ:AKTS - Free Report) by 2.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,070,219 shares of the technology company's stock after selling 91,129 shares during the quarter. Aktis Oncology accounts for 14.9% of Blue Owl Capital Holdings LP's portfolio, making the stock its 2nd largest position. Blue Owl Capital Holdings LP owned about 5.75% of Aktis Oncology worth $98,953,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State of Wyoming purchased a new stake in shares of Aktis Oncology in the 2nd quarter valued at approximately $32,000. Deutsche Bank AG boosted its position in shares of Aktis Oncology by 49.3% in the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company's stock worth $678,000 after buying an additional 6,942 shares during the period. Great Lakes Advisors LLC purchased a new position in shares of Aktis Oncology during the second quarter valued at $1,406,000. Bank of New York Mellon Corp grew its holdings in shares of Aktis Oncology by 14.8% during the second quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company's stock valued at $1,587,000 after buying an additional 6,349 shares in the last quarter. Finally, BlackRock Inc. raised its position in Aktis Oncology by 7.9% during the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company's stock valued at $73,431,000 after buying an additional 166,231 shares during the period. 28.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on AKTS shares. Wall Street Zen lowered Aktis Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They issued an "outperform" rating on the stock. Weiss Ratings raised shares of Aktis Oncology from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday, June 23rd. Wedbush initiated coverage on shares of Aktis Oncology in a report on Wednesday. They set an "outperform" rating and a $35.00 price target for the company. Finally, Raymond James Financial assumed coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a "strong-buy" rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Aktis Oncology currently has an average rating of "Moderate Buy" and an average target price of $35.00.

Aktis Oncology Stock Performance

Shares of AKTS opened at $24.00 on Friday. The firm has a market cap of $1.28 billion and a PE ratio of -29.27. The firm's 50 day moving average price is $25.45 and its 200 day moving average price is $21.27. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last posted its earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. On average, sell-side analysts anticipate that Aktis Oncology will post -1.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Aktis Oncology

In other news, Director Ken Herrmann sold 4,856 shares of the company's stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the sale, the director owned 3,506 shares in the company, valued at approximately $86,107.36. This represents a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.30% of the stock is owned by corporate insiders.

About Aktis Oncology

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

Want to see what other hedge funds are holding AKTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aktis Oncology (NASDAQ:AKTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source